Aileron Announces Poster Presentations at Two Scientific Conferences in November
October 19 2018 - 8:00AM
Poster presentation at the Society for
Immunotherapy of Cancer (SITC) Annual
MeetingPoster presentation at the 2018
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics
Symposium
Aileron Therapeutics (Nasdaq: ALRN), the clinical stage leader in
the discovery and development of engineered cell-penetrating
peptides, today announced that two abstracts for the company’s lead
drug, ALRN-6924, will be presented, one each at the Society for
Immunotherapy of Cancer (SITC) and the 2018 EORTC/NCI/AACR
Symposium in November.
Society for Immunotherapy of Cancer (SITC) Annual
Meeting Poster Title:
“The stapled peptide ALRN-6924,
a dual inhibitor of MDMX and MDM2, displays immunomodulatory
activity and enhances immune checkpoint blockade in syngeneic mouse
models” Session
Date:
Nov. 9th, 8 a.m.– 8 p.m. and Nov. 10th, 8 a.m.– 8:30 p.m. local
timeLocation:
Walter E. Washington
Convention Center, Hall E EORTC/NCI/AACR Symposium
DetailsPoster
Title:
“Harnessing the anticancer activity of the stapled peptide
ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational
combination strategies for breast cancer and other
malignancies”Session
Name:
Molecular Targeted Agents - PART IISession
Date:
November 16th, 10:00 a.m.-2:00 p.m. local
timeLocation:
The Convention Centre
Dublin, Exhibition Hall
About ALRN-6924ALRN-6924 is a first-in-class
product candidate designed to reactivate wild-type p53 tumor
suppression by disrupting the interactions between p53 and its two
primary suppressor proteins, MDMX and MDM2. Aileron believes
ALRN-6924 is the first and only product candidate in clinical
development that can equipotently bind to and disrupt the
interaction of MDMX and MDM2 with p53. ALRN-6924 is currently being
evaluated in multiple clinical trials for the treatment of acute
myeloid leukemia (AML), advanced myelodysplastic syndrome (MDS) and
peripheral T-cell lymphoma (PTCL). For information about its
clinical trials, please visit www.clinicaltrials.gov.
About AileronAileron is a clinical-stage
biopharmaceutical company advancing a proprietary platform capable
of engineering cell-penetrating alpha-helical peptides to address
previously undruggable intracellular targets in oncology and other
therapeutic areas. Our alpha-helical peptides are engineered to
create potentially safe and effective therapies for patients. We
leverage our internal expertise in peptide chemistry to design and
develop specialized peptides with unique drug-like properties such
as ALRN-6924. Our current focus is to improve the standard of care
for patients with hematological and solid tumors. For more
information, visit www.aileronrx.com and for more information
about our clinical trials, please
visit www.clinicaltrials.gov.
Forward-Looking Statements Statements in this
press release about Aileron's future expectations, plans and
prospects, as well as any other statements regarding matters that
are not historical facts, may constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements about the Company’s strategy and clinical development
plans. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including whether Aileron’s cash resources will be
sufficient to fund its continuing operations for the periods and/or
trials anticipated; whether results obtained in preclinical studies
and clinical trials will be indicative of results obtained in
future clinical trials; whether Aileron’s product candidates will
advance through the clinical trial process on a timely basis, or at
all; whether the results of such trials will warrant submission for
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether Aileron's product
candidates will receive approval from regulatory agencies on a
timely basis or at all; whether, if product candidates obtain
approval, they will be successfully distributed and marketed;
whether the Company will be able to enter into additional
collaborations; and other factors discussed in the "Risk Factors"
section of Aileron's quarterly report on Form 10-Q for the period
ended June 30, 2018, filed on August 7, 2018, and risks described
in other filings that Aileron may make with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Aileron
specifically disclaims any obligation to update any forward-looking
statement, whether because of new information, future events or
otherwise.
Investors:Aileron TherapeuticsDon Dougherty,
CFO617-995-0900ddougherty@aileronrx.com
Hans C. VitzthumLifeSci Advisors, LLC.617-535-7743
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Sep 2023 to Sep 2024